» Articles » PMID: 18835834

Impact of AB0-blood Group Incompatibility on the Outcome of Recipients of Bone Marrow Transplants from Unrelated Donors in the Japan Marrow Donor Program

Overview
Journal Haematologica
Specialty Hematology
Date 2008 Oct 7
PMID 18835834
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the AB0 blood group is one of two major antigen systems of relevance for transplantation in humans, there are still conflicting data concerning the influence of AB0 incompatibility on transplant outcome. This study investigated the effect of AB0 incompatibility in recipients of bone marrow transplants from unrelated donors.

Design And Methods: We retrospectively analyzed data from 5,549 patients who underwent bone marrow transplantation from unrelated donors in the Japan Marrow Donor Program.

Results: Overall survival rates in the group with major and minor mismatches were significantly lower than the rate in the AB0-identical group (AB0-identical 63.0%; major mismatch, 56.9%; minor mismatch, 57.1% at 1 year). Treatment-related mortality was higher in the major and minor mismatch groups, but there was no significant difference in the rate of relapse. Cox proportional hazards modeling showed that both major and minor AB0 incompatibility were significant risk factors for transplant-related mortality, independently of disease, patients' age, and HLA incompatibility. Delayed engraftment of neutrophils, platelets, and erythrocytes was observed in transplants with major incompatibility. There was a high incidence of grade 3 and 4 acute graft-versus-host disease in the groups with major and minor mismatches, which was caused by a high incidence of stage 2 to 4 liver graft-versus-host disease. Interestingly, the risk of grade 2 to 4 graft-versus-host disease in the major mismatch group was higher in patients with early engraftment of erythrocytes. Among the patients receiving reduced-intensity conditioning, the transplant-related mortality was also increased in AB0-incompatible transplants.

Conclusions: Major and minor AB0 incompatibility have specific effects on transplant-related mortality and acute graft-versus-host disease in recipients of bone marrow transplants from unrelated donors.

Citing Articles

Outcomes in patients undergoing hematopoietic stem cell transplantation for myelodysplastic syndromes.

Karumathil S, Kulkarni U, Selvarajan S, Lionel S, Devasia A, Aboobacker F Blood Cell Ther. 2025; 8(1):147-159.

PMID: 40061177 PMC: 11883483. DOI: 10.31547/bct-2024-002.


ABO blood groups and galectins: Implications in transfusion medicine and innate immunity.

Arthur C, Hollenhorst M, Wu S, Jajosky R, Nakahara H, Jan H Semin Immunol. 2024; 74-75:101892.

PMID: 39405833 PMC: 11808837. DOI: 10.1016/j.smim.2024.101892.


ABO incompatibility haploidentical peripheral blood stem cell transplantation combined with a single cord blood unit for severe aplastic anemia patients.

Wang X, Wang Y, Saulat A, Liu R, Ren J, Zhu H SAGE Open Med. 2024; 12:20503121241255807.

PMID: 38826828 PMC: 11143862. DOI: 10.1177/20503121241255807.


Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.

Finazzi M, Weber A, Pavoni C, Grassi A, Mico M, Algarotti A Bone Marrow Transplant. 2024; 59(6):751-758.

PMID: 38402345 PMC: 11161407. DOI: 10.1038/s41409-024-02247-w.


A retrospective study to assess the impact of ABO incompatibility on outcomes of allogeneic peripheral blood stem cell transplants at a tertiary care hospital in Western Maharashtra.

Nalukettil B, Biswas A, Asthana B, Kushwaha N, Baranwal A, Sharma S Asian J Transfus Sci. 2024; 17(2):202-209.

PMID: 38274976 PMC: 10807530. DOI: 10.4103/ajts.ajts_134_21.